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For small – low molecular weight – molecule medicines a robust regulatory system has evolved over the
years. This system guarantees high and constant quality of our (generic) medicines. Pharmaceutical
equivalence and bioequivalence assessment are the pillars under that system. But there are complex
medicines where the question of equivalence is more challenging to answer. For biologicals the paradigm
of similarity rather than equality (the emergence of ‘biosimilars’) was developed in the past decade. This
has been a program where an evolutionary, science based approach has been chosen by the frontrunner
regulatory body, the EMA, with a ‘learn and conﬁrm’ character.
In addition, there is another group of complex drugs, the non-biological complex drugs, NBCDs, where
the generic paradigm can be challenged as well. The NBCDs are deﬁned as: 1. consisting of a complex
multitude of closely related structures; 2. the entire multitude is the active pharmaceutical ingredient;
3. the properties cannot be fully characterized by physicochemical analysis and 4. the consistent, tightly
controlled manufacturing process is fundamental to reproduce the product. NBCDs encompass product
families such as the glatiramoids, liposomes, iron–carbohydrate colloids and many candidates of the
group of the upcoming nanoparticulate systems. Following the main principles of regulatory pathways
for biologicals (with appropriate product-by-product adjustments), instead of that for small molecules,
would be the more logical strategy for these NBCDs.
The status and outstanding regulatory issues for biosimilars and NBCD-similars/follow on versions
were discussed at a conference in Budapest, Hungary (October 2014) and this commentary touches upon
the issues brought up in the presentations, deliberations and conclusions.
 2015 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction International Pharmaceutical Federation (FIP) and the EuropeanThis conference was organized in Budapest (October 2014) by
the department of Pharmaceutics of Semmelweis University with
other Hungarian science organizations and under the auspices of
the American Association of Pharmaceutical Scientists (AAPS), theFederation of Pharmaceutical Sciences (EUFEPS). It brought aca-
demic, industrial (both the innovator and follow-on companies)
and regulatory experts together to discuss the topic: ‘complex drug
products and similarity’, a topic that is at present high on the
agenda of the regulators and health care policy decision makers.
2. Small molecule medicines: a mature system for approval of
generic/follow-on versions
Over the years the regulatory policies for the development of
generic versions of small molecule medicines have evolved and a
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cept of pharmaceutical equivalence and bioequivalence (left side
of Fig. 1). This paradigm is based on the assumption that the
molecular structure of the bioactive molecule is known and
can be exactly reproduced and fully characterized. Typically, it
is one well-deﬁned molecule, the active pharmaceutical ingredi-
ent, embedded in an appropriate formulation. Mixtures (e.g.
enantiomers of chiral molecules) may occur, but their exact
composition should be known and be constant. Regulatory
experts from all over the globe (e.g. from FDA, EMA, WHO) have
developed their guidance documents to assure equality in terms
of quality, efﬁcacy and safety between the innovator’s and vari-
ous generic versions of these medicines. The different guidance
documents have a common philosophy. But, even with their
common science base, there are differences in position, e.g.
regarding the rules for biowaiver policies. In general, no preclin-
ical and clinical trials to compare the performance of the generic
drug with the innovator product are requested. However, for
some small molecule formulations and speciﬁc devices authori-
ties are cautious to rely on the pharmaceutical quality/bioequiv-
alence protocols alone. In this context narrow therapeutic index
drugs, controlled release and modiﬁed release formulations, skin
patches, inhalers and multi-ingredient products are mentioned
(Dunne et al., 2013). Thus, there is a worldwide clear, common
denominator for the regulatory process to give a market autho-
rization to generic small molecule preparations. But, in spite of
extensive efforts e.g. through the ICH, the International
Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use, no real, total
global consensus has been reached yet. However, work is in pro-
gress (cf. the EUFEPS Global Bioequivalence Harmonization
Initiative, March 2015).3. Complex drugs: a regulatory framework under development
Next to these small molecule medicines, complex drugs have
been developed and the regulatory challenges that come with eval-
uating these complex drugs were the major discussion points for
this conference. While equal or identical are the key terms for small
molecule medicines, similar is the key word for complex drugs. And
the question is: how similar is similar?Fig. 1. Adapted from Schellekens et al., 2011: Similarity approach for complex drugs. Th
the context of biosimilars, establishes biosimilarity by using an extensive set of decisive
involve a large battery of state-of-the-art physicochemical, analytical, and functional mIn the regulatory world, there is a dichotomy between two
groups of complex drugs. Those complex drugs that are produced
through living organisms (biologicals) and the non-biological com-
plex drugs (NBCDs): complex drugs that are not produced through
living organisms, but through a fully synthetic process. In particu-
lar, the advent of follow-on versions of biologicals has drawn a lot
of attention to the class of complex medicines and the inherent
regulatory challenges. The lectures and discussions during the con-
ference formed the basis of the following text on the history and
current developments of this fast growing area in the world of
medicines. A general discussion on comparability/similarity of bio-
logicalswill be followed by a list of ‘outstanding issues’ that are still
to be resolved: bioquestionables, comparability and product attri-
bute drift, interchangeability and substitution, extrapolation and
naming. This will be followed by a description of the status of
the legislation and practical experience with non-biological com-
plex drugs (NBCDs) and attention will be paid to the similarities
and differences between the existing regulatory frameworks for
follow-on versions of biologicals and NBCDs.4. Biologicals and follow-on versions
In the Budapest conference the issues around the follow-on ver-
sions of biologicals were ﬁrst discussed as the regulatory frame-
work has been more extensively debated in the literature than
the NBCD-regulations. Drs. Greiner, Crommelin and Declerck
addressed different aspects of the legislature and regulatory
rulings regarding the comparability of biologicals and their
follow-on versions. As these speakers pointed out, over the last
decade a lot of progress has been made to develop such a regula-
tory framework but there are quite a few outstanding issues that
will be part of the text below.
4.1. The EMA as frontrunner
The EMA has taken the lead in building a regulatory structure
for biologicals starting as early as 2001 with Directive
2001/83/EC (EMA, 2001) where the term biological is deﬁned: ‘A
biological medicinal product is a product, the active substance of
which is a biological substance. A biological substance is a
substance that is produced by or extracted from a biological sourcee term ‘ Totality of (the) evidence’ has been deﬁned as: A scientiﬁc principle that, in
methods sensitive enough to detect relevant differences, if present. These methods
ethods and clinical studies (from Weise et al., 2014).
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quality a combination of physico-chemical–biological testing,
together with the production process and its control’. And then
the basis for the development of guiding documents for
follow-on biologicals/biosimilars was formulated: ‘Where a biolog-
ical medicinal product which is similar to a reference biological
product does not meet the conditions in the deﬁnition of generic
medicinal products, owing to, in particular, differences relating to
raw materials or differences in manufacturing processes of the bio-
logical medicinal product and the reference biological medicinal
product, the results of appropriate pre-clinical tests or clinical tri-
als relating to these conditions must be provided. . . .’ (directive
2004/27/ec article 10 4; 31 March (EMA, 2004)). The central proce-
dure through the EMA is the legal route to obtain market approval
for a biological or biosimilar medicinal product.
The EMA uses the term biosimilar for EMA approved biologicals.
This term was deﬁned by Crommelin et al. (2014) as: ‘A similar
biological medicinal product (also known as biosimilar) is a biolog-
ical product authorized by an abbreviated regulatory pathway
requiring similarity to an already licensed biological product (the
reference product) in physicochemical, in vitro and in vivo biolog-
ical characteristics, and clinical data showing similarity in efﬁcacy,
safety, and immunogenicity’. The use of this term (biosimilar) is
restricted to products that underwent a rigorous test program
e.g. based on the EMA guidelines for biosimilars (Weise et al.,
2011). These guidelines are divided in three sections: ‘overarching
biosimilar guidelines’, ‘product speciﬁc guidelines’ and ‘other
guidelines relevant for biosimilars’ (EMA, 2015). These documents
are regularly updated and expanded.
The EMA has been in the lead in deﬁning the guidelines for
biosimilars and 21 biosimilars were approved in the EU (per
10/2014). Countries as Japan (5 biosimilars), Canada (3 s entry
biologicals) and Australia (8 biosimilars) followed the principles
of the EMA framework. The EMA rejected a number of applications
or applicants withdrew their application. The applications for
interferon-beta and interferon-alfa (BioPartners) were rejected
and Marvel LifeSciences Ltd (India) withdrew its application for
insulin follow-on products. More details about the approved and
rejected/withdrawn applications can be found in the epars
(European Public Assessment Reports) published by the EMA and
in Heinemann and Hompesch (2011).Fig. 2. ‘Biosimilar development process. The development of a biosimilar relies on creat
development of a biosimilar to ﬁt the chosen speciﬁcations. There is no access to, nor ne
essential, and later development cannot compensate for this initial generation of a ‘‘high
the initial development becomes more challenging, and the likelihood that multiple iter4.2. Similarity between the regulatory views worldwide?
And other initiatives? In 2009, the WHO published guidelines to
evaluate ‘‘similar biotherapeutic products’’ (SBP). This publication
was e.g. the basis for the Korean legislation (Wang and Chow,
2012) and countries in Latin America (Desanvicente-Celis et al.,
2013). And in the USA a framework for biosimilars (indeed using
the same term) is being set up by the FDA and the ﬁrst ‘tentative’
approval have been announced (for ﬁlgrastim) (FDA, 2015a).
Unfortunately, the EMA and FDA systematics are different and
there is deﬁnitely a need for harmonization. But, both agencies
recommend two important ways to proceed: use a ‘stepwise
approach’ and ‘totality of evidence’ as guiding principles to obtain
market approval for biosimilars. That means that (on a
case-by-case basis) the results obtained in comparing product
quality, outcome of safety and efﬁcacy experiments are being eval-
uated and being used for further planning of necessary/required
experiments (cf. Fig. 2).
4.3. Bioquestionables
The term bioquestionables is deﬁned as: A copy version of a
therapeutic protein, which has not been developed and assessed
in line with the scientiﬁc principles of a comparative development
program against a reference product showing similarity in quality,
safety and efﬁcacy. In certain countries the quality of the approval
process for follow-on biologicals has been questioned. E.g. 12
copies of erythropoietin (‘bioquestionables’) approved through a
classical generic regulatory pathway in Thailand were compared
and signiﬁcant variation in physico-chemical and chemical charac-
teristics was found (Halim et al., 2014). The authors state that ‘This
comparison study supports a link between the quality attributes of
copy rhEPO products and their immunogenicity’. Immune reac-
tions against epo lead to pure red cell aplasia, PRCA, a serious, life
threatening disease.
4.4. Comparability and product attribute drift
The quality of a biological product depends on a robust, well
controlled manufacturing process including the downstream pro-
cessing and ﬁlling and ﬁnishing steps. But these processes mayion of a design space based on analysis of the reference product and then iterative
ed for, originator data at any point in this process. The early process development is
ly similar’’ candidate product. As the complexity of the reference product increases,
ations will be needed increases (adapted from McCamish and Woollett, 2011)’.
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authorities. E.g., for Rebif™ more than 35 changes were reported
to the EMA since its launch. Among those: changes in the host cells,
active molecule, speciﬁcations and formulation (cf. EMA, 2014).
The innovator is requested to show ‘comparability’ between the
product attributes before and after a change. Assessment of com-
parability can be based on a combination of analytical testing, bio-
logical assays, and in some cases non-clinical and clinical data.
Schiestl et al. (2011) showed physico-chemical differences in three
innovator products after manufacturing process changes with no
changes in the product label. This drift in innovator product attri-
butes may have interesting consequences. The innovator and a
new biosimilar product show similar, but not equal characteristics.
If the innovator manufacturing process, or mutatis mutandis, the
biosimilar manufacturing process changes, then the two product
characteristics may drift so far apart that similarity cannot be pre-
served: divergence over time occurs. The implications of this drift
have not been discussed in depth in the existing literature.
Our analytical capabilities to characterize pharmaceutical pro-
teins are growing at a rapid pace (Berkowitz et al., 2012; Beck
et al., 2015). In the conference Dr. Sandra showcased the enormous
resolution of today’s mass spectrometry (MS)/chromatography
combinations when characterizing pharmaceutical protein formu-
lations and the increasing power of MS to identify the structure
and quantity of the different components. These are very powerful
tools, indeed, not only to identify structural differences between
the innovator and biosimilar product, but also to monitor batch
to batch quality in detail. And then the question should be asked:
if differences are detected in comparability studies between inno-
vator/innovator, innovator/biosimilar, or biosimilar/biosimilar
products: what does that do to their clinical performance? Are
(pre)clinical tests necessary to show similarity in clinical outcome?
Subsequently, drs. Ferrari and Bansal worked out a number of prac-
tical cases where state of the art equipment for protein analysis
was used to characterize proteins and they identiﬁed and dis-
cussed outstanding issues e.g. ‘carry over’, sensitivity and linearity
of response.4.5. Interchangeability and substitution
The following deﬁnition of interchangeability is proposed:
‘Interchangeability can be at the population level meaning both
products can be used for treatment for the same condition in the
same population. Interchangeability at the individual level means
that for an individual patient, the products can be alternated or
switched. Interchangeability at the individual level is a condition
for substitution’ (Crommelin et al., 2014). And ‘Substitution is a
policy to allow replacement at the individual level of a medicinal
product for a similar/bioequivalent product’ (Crommelin et al.,
2014). Clarity about this issue is of key importance to the pharma-
cist when dispensing a prescribed medicinal product. When the
EMA recommends market approval for a biosimilar, this doesn’t
mean that the product is automatically interchangeable and can
be substituted throughout the EU. To decide on interchangeability
between an innovator’s product and a biosimilar is a competence
of each individual state in the EU and is beyond the authority of
the EMA. And the state policies differ markedly per country and
are subject to change over time (Niederwieser and Schmitz,
2011). The European map shows all kind of options varying from
‘substitution under certain conditions’ in France (GaBI, 2014) to
‘no substitution allowed for biologicals’. In the US the decision on
substitution is a state responsibility and different states have
passed legislation. Here again, differences in state legislation over
the country seem to appear and the discussion is still ongoing
(GaBi, 2015).4.6. Extrapolation
Recently, the issue of ‘extrapolation of indication’ has been sub-
ject of an intense debate and at the conference different aspects
were discussed by the speakers. First a deﬁnition: ‘extrapolation
is the possibility to use the clinical data showing safety and efﬁcacy
in one indication (reference indication) to claim safety and efﬁcacy
in other indications’ (Crommelin et al., 2014). This discussion was
in particular fuelled by the differences in opinion between the EMA
and Health Canada regarding the extrapolation of indications for
the biosimilar version of inﬂiximab, approved both in Europe and
Canada, but where the Canadian authority rejected the proposal
to extrapolate the indication to intestinal bowel disease, and the
EMA did approve the extrapolation. Weise et al. (2014) provide
insight in the philosophies behind these decisions and list the
arguments. But, here again, this is another example where a glob-
ally harmonized decision would have been the preferred outcome.
4.7. Naming
The naming of biosimilars (next to their brand name) causes an
intense debate. Worldwide different approaches are being fol-
lowed, often with the WHO-INN as source of inspiration. This leads
to confusion and might cause medication errors. E.g., an epoetin
alfa in the EU is registered as epoetin lambda in Australia. High
time for a global initiative with WHO in the lead. In July 2014
the WHO published a draft document where – on a voluntary basis
– the different biosimilars would be named with the INN name, fol-
lowed by a WHO assigned ‘biological qualiﬁer’ (BQ). The discussion
is still ongoing (after an October 2014 WHO consultation meeting)
and no ﬁnal WHO document has seen the light yet.5. Concluding remarks re biological complex drugs
A lot has been achieved regarding the pathways to provide the
patient with safe, efﬁcacious and high quality biologicals, be it
innovator products or their biosimilar(s). Today the EMA has most
experience with designing and evaluating the regulatory path. It is
an evolutionary process: learning and conﬁrming. WHO followed
suit and FDA is in the process of setting up its own system, similar
but not identical to the EMA path. Thus there is – and will be – no
worldwide accepted science based regulatory system for biologi-
cals in place.6. NBCDs: non-biological complex drugs
During the ﬁrst day of the conference, six lectures and a panel
discussion were dedicated to NBCDs, i.e. by drs. De Vlieger,
Mühlebach, Weinstein, Gaspar, McNeil and Zoubek. Dr. De
Vlieger introduced the goals and activities of the NBCDs working
group (TI Pharma, 2015) and deﬁned the term NBCD. He listed
the following key attributes for a NBCD:
1. it consists of a multitude of closely related structures,
2. the entire complex is the active pharmaceutical ingredient,
3. the properties cannot be fully characterized by physicochemical
analysis,
4. the well-controlled, robust manufacturing process is funda-
mental to reproduce the product.
NBCDs are a ‘mixed bag’ of medicinal products; they cover a
number of ‘medicine-families’ such as the glatiramoids for subcu-
taneous injections, iron–carbohydrate-complexes for i.v. adminis-
tration, liposomes, polymeric micelles, swelling polymers (oral
administration), albumin–cytostatic complexes and other
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dry powder inhalers, ocular/intravenous emulsions and dermal
patches are seen as NBCDs as well. More detailed information
about NBCDs can be found in the book published in the spring of
2015: ‘Non-biological complex drugs; the science and the regula-
tory landscape’ (Crommelin and de Vlieger, 2015). Drs.
Mühlebach and Weinstein discussed speciﬁc NBCD families, see
below, while Dr. McNeil demonstrated how within the
Nanotechnology Characterization Lab, NCI–NCL, techniques are
developed to physico-chemically characterize nanomedicines and
to monitor their behavior in vivo. Finally, Dr. Gaspar gave an over-
view of the regulatory status of the approval process of innovator
and follow-on liposome products and other nanoparticulate
medicines.6.1. The legal landscape
In the past the complications with the approval of NBCD inno-
vator products have been recognized by the EMA and regulatory
routines for such medicinal products have been developed over
the years. Dr. Pita from EMA gives his (personal) views on the posi-
tion of NBCDs in the regulatory framework of the EMA in a recent
publication (Pita, 2015). The advent of follow-on versions of these
NBCDs asked for speciﬁc rulings for approval with the requested
extra information provided on a case-by-case basis. The EMA has
not formally classiﬁed certain product families (cf. above) as
NBCDs. But, nanomedicines are often mentioned in the context of
NBCDs. The EMA tends to refer to the biosimilar framework when
issues regarding similar-NBCDs (follow-on versions of NBCDs) are
discussed. A concrete difference with biosimilars in the European
legislation is that clear similar-NBCD applications are not necessar-
ily following the central procedure and may receive marketing
approval through the decentralized route. That happened in the
past (e.g. in France 5 brands of iron-sucrose are marketed) and
recently, an iron-sucrose product was approved for the Swedish
market through the national procedure and considered ‘as similar
to the innovator product’ (PAR, 2012). No clinical data were
requested by the Swedish authorities. In the PAR (public assess-
ment report) reference is made to the EMA Reﬂection paper (see
below).
For the FDA NBCDs are not formerly recognized. Complex drugs
follow the 505(b)(1) or 505(b)(2) route for NDA and the 505(j)
route for ANDA. For both routes (NDA/ANDA) additional informa-
tion compared to the standard small molecule package may be
requested. That is decided on a case-by-case basis. However, for
certain NBCD product families such as liposomes, different iron
carbohydrates (iron sucrose, iron gluconate, ferumoxytol) and
cyclosporine ophthalmic emulsions, draft guidance documents
have been issued, which were open for discussion while drafted.
This helps in establishing science based regulatory procedures for
NBCD families.
Information on NBCD regulations in other countries of the
world has not been collected and analyzed yet. It sufﬁces to state,
that there is a need to obtain such an overview as there may be
NBCD-questionables (cf. bio-questionables) on the market. In the
following sections on NBCD product families some examples of
NBCD-questionables will be presented. Are they the tip of the
iceberg?7. NBCD product families
7.1. Liposomes
Liposomes may be seen as frontrunners for the now upcoming
nanomedicines family (e.g. polymeric micelles and colloidal golddispersions) and much of the experience obtained with liposome
registration may – in adjusted form – be applied to submissions
for other nanomedicine systems. Dr. McNeil explained that the
NCL is working on the development of analytical techniques and
procedures to characterize liposomes/nanomedicines and to mea-
sure relevant aspects of their performance in vitro and in vivo
(Table 1), often to be part of the data package to support submis-
sion to the regulator.
The ﬁrst guidance paper published for liposomes appeared in
2002 (FDA CDER, 2002). This document dealt with the ‘liposome
drug products: chemistry, manufacturing, and controls; human
pharmacokinetics and bioavailability; and labeling documentation’
and explicitly did not provide information on clinical efﬁcacy and
safety studies and nonclinical pharmacology and/or toxicology
studies. The 505 (b)(1) or (b)(2) pathways are available. Later
another guidance document was drafted (FDA CDER, 2014), which
speciﬁcally focused on the development of follow-on versions of
doxorubicin liposomes through the 505(j) pathway. Here again,
this document does not provide information regarding clinical efﬁ-
cacy and safety studies. In the EU innovative and follow-on lipo-
some products follow the centralized procedure. For innovator
liposome products no speciﬁc guidance documents are available.
For follow-on versions of doxorubicin liposomes a ‘reﬂection
paper’ was issued in 2009/2013 (EMA, 2013). From this reﬂection
paper on can read that proper handling of issues like ‘‘sameness’’
of the follow-on product and reference product, a ‘stepwise devel-
opment approach’ and ‘totality of evidence’ is important and key to
successfully submit the dossier and receive approval.
In the EU and USA 11 innovator liposome products have been
registered (Crommelin et al., 2015). In the USA one follow-up pro-
duct is approved in a two step process (Lipodox as follow-on ver-
sion of Doxil). Interestingly, the dossier of Lipodox was rejected
by the EMA (EMA, 2011). Here no bioequivalence for free doxoru-
bicin could be established for Lipodox and Caelyx, which is (just)
the European brand name of Doxil: produced by the same manu-
facturer in the USA. Thus, two different decisions were taken for
the same follow-on product. In other parts of the world like
India, Taiwan, Argentina and China follow-on versions of doxoru-
bicin and amphotericin liposomes are on the market. But little
information can be found on the registration criteria for these lipo-
some products. So far, WHO has not come out with regulations, but
the model of the World Health Organization (WHO) prequaliﬁca-
tion system could be considered.
In short, both in the EU and USA material has been published to
guide both innovator and follow-on liposome product manufactur-
ers to submit a dossier.
7.2. Glatiramoids
The glatiramoid class of drugs was presented by Dr. Weinstein.
She focused on quality attributes of glatiramoids. Glatiramoids are
non-biological complex drugs (NBCDs) comprising of a highly com-
plex mixture of copolymers based on four amino acids (Ala, Tyr,
Lys and Glu) of varying sequences and sizes obtained by a process
of polymerization followed by partial hydrolysis. The ﬁrst and
most thoroughly studied glatiramoid, glatiramer acetate
(Copaxone, Teva Pharmaceutical Industries, Ltd.) was approved
for treatment of relapsing–remitting multiple sclerosis, an autoim-
mune disorder. Copaxone is an extremely complex mixture of
these four amino acid copolymers. Its components are neither fully
identiﬁable nor quantiﬁable even by the most modern analytical
techniques. The mechanism of action and the active components
responsible for its clinical effect are still uncertain in spite of exten-
sive research and a multitude of publications in peer-reviewed
journals. Therefore, the entirety of the Copaxone constituents is
considered to be the API. The composition of Copaxone is
Table 1
NCL assay cascade.
Size/Size Distribution
 Dynamic Light Scattering (DLS)
 Electron microscopy (TEM, SEM, crvo)
 Atomic Force Microscopy (AFM)
 Field Flow Fractionation (FFF), SEC-MALLS
Composition
 TEM with EDS
 Inductively coupled plasma-mass spec. (ICP-MS)
 Spectroscopy (NMR, CD, Fluorescence, IR, UV–vis
Purity
 Chromatography
 Capillary Electrophoresis
Surface Chemistry
 Biacore
 Zeta Potential
Stability
 Stability can be measured with any number of instruments
with respect to time, temperature, pH, etc.
Sterility
 Bacterial/vital/mycoplasma
 EndotoxinCell uptake/distribution
 Cell binding/internalization
 Targeting
Hematology
 Hemolysis
 Platelet aggregation
 Coagulation
 Complement activation
 Plasma protein binding
Immune cell function
 Cytokine induction
 Chemotaxis
 Phagocytosis
 Leukocyte Proliferation
 Leukocyte Procoagulant activity
Toxicity
 Oxidative stress
 Cytotoxicity
 Autophagy
Initial disposition study
 Tissue distribution
 Clearance
 Half-life
Immunotoxicity
 Local lymph node proliferation assay
 T-cell dependent antibody response
 Rabbit pyrogen test
Single and repeat dose toxicity
 Blood chemistry
 Hematology
 Histopathology (42 tissues)
 Gross pathology
Efﬁcacy
 Therapeutic
 Imaging
Pharmacology
 Clinical Tx cycle
 NP quantitation methods
 PK parameters
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process. Being a synthetic mixture of a variety of structurally related
components, Copaxone fulﬁlls all criteria of a NBCD (see above).
Throughout the world, however outside the EU and the USA,
purported follow-on versions of Copaxone are available, e.g.
Glatimer, Escadra, and Probioglat. Publications (cf. Weinstein
et al., 2015) compare the quality of these follow-on products with
regard to physicochemical composition. Various techniques,
including HPLC (high performance liquid chromatography), IEF
(iso-electric focusing), CE (capillary electrophoresis), AFM (atomic
force microscopy), DLS (dynamic light scattering) and
two-dimensional IMMS (ion mobility mass spectrometry) show
substantial differences between Copaxone and the follow-on
products, whereas Copaxone batches fall within its inherent
microheterogeneity range. The biological impact of Copaxone ver-
sus the follow-on versions, was shown to be different as well, e.g.
in transcriptional proﬁles (Towﬁc et al., 2014). There are also indi-
cations of ADR (adverse drug reactions) increase when Probioglat
was used instead of Copaxone in Mexico (Citizens Petition,
2014). Are these purported follow-on versions indeed similar to
Copaxone? These publications suggest that the answer is: No.
7.3. Iron carbohydrate complexes
The last NBCD product family to be discussed in this commen-
tary is the family of the intravenously administered iron–carbohy-
drate colloids (Dr. Mühlebach). Iron–carbohydrate colloids are
(1) non-biological complex drugs,
(2) carbohydrate coated polynuclear iron(III)-oxo-hydroxide
cores with a still unknown structure,(3) nanosized dispersions,
(4) pro-drugs: highly reactive active Fe3+ to be released in a con-
trolled manner upon administration,
(5) the result of laborious, tightly controlled manufacturing
processes.
In the body iron transport/storage is mediated through different
speciﬁc proteins like transferrin and ferritin. The released iron is
transported, distributed, and stored in reservoirs in the MPS/RES
(mononuclear phagocyte system/reticulo-endothelial system).
This distribution pattern is linked to their nanoparticular properties
which are dependent on their speciﬁcmanufacturing process. If iron
delivery is not targeted in the same way to deﬁned structures, cells
and pools, the iron product will show clinically meaningful differ-
ences.A changedproduct availability anddispositionmaycause iron
overload or undesired storage (e.g. hemosiderosis) affecting efﬁcacy
and safety. Oxidative stress may occur when the biological acceptor
proteins like transferrin are saturated. Labile iron, non-transferrin
bound iron, consist of highly reactive species andmay induce oxida-
tive and/or nitrosative stress contributing to inﬂammation and
apoptosis. This was shown by Toblli et al., 2012 and Toblli et al.,
2015 in non-clinical investigations in non-anemic rats when com-
paring the originator iron sucrose and follow on products.
Iron carbohydrate complexes are made out of different
mono- or polymeric ‘‘sugars’’ like sucrose, gluconate, dextran,
carboxymaltose, isomaltoside or polyglucosesorbitol stabilizing
the polynuclear oxyhydroxy core and affecting the kinetics and
(dose) tolerance of the product. All these innovator’s colloidal
products are registered in the EU. Interestingly, some follow-on
versions have been authorized via the generic regulatory pathway
(national route/decentralized procedure) without considering the
16 D.J.A. Crommelin et al. / European Journal of Pharmaceutical Sciences 76 (2015) 10–17consequences of their complex, colloidal/nanoparticulate struc-
ture. A number of studies appeared lately where the in vivo perfor-
mance of follow-on versions (iron sucrose similars) of the
iron-sucrose innovator product (iron sucrose innovator) was com-
pared in clinical settings (Rottembourg et al., 2011; Martin-Malo
et al., 2012; Stein et al., 2012; Lee et al., 2013). In clinical studies
differences were found with an increase in ADR/reduction in efﬁ-
cacy in the case of the follow-on product. One may wonder on
the basis of what documentation these follow-on versions were
registered.
Is the situation changing? Recently, both EMA (EMA, 2011,
2013a) and FDA (FDA, 2013) have issued ‘reﬂection papers’ and
‘draft guidance’ documents, respectively, regarding data require-
ments. It is hard to understand with all the clinical relevant differ-
ences available and also with a referral procedure for all i.v. iron
products in place (EMA, 2013b), that still market authorization of
an iron carbohydrate follow-on version is granted by the biblio-
graphic pathway in the EU. That happened in Sweden with new
approvals of iron carbohydrate products (dextran derivatives) in
their life cycle development (Cosmofer and MonoFer) and as
consequence for Diafer. The inappropriateness of approval via
the bibliographic documentation route (article 10a of Directive
2001/83/EC 10a) for such colloidal NBCDs follow-ons was pointed
out by Dr. Zoubek, an experienced regulatory consultant. Recently,
the FDA contracted out a study on the comparison of the
iron-gluconate innovator product and the follow-on version
(FDA, 2015b). It calls for ‘‘a prospective, randomized, 2-way cross-
over study to compare plasma NTBI (non-transferrin bound iron)
levels in hemodialysis patients treated with the follow-on and ref-
erence drug’’ to evaluate the products, and, in addition, the FDA
evaluation tools and – to gain more insight into pros and cons –
a direct head to head evaluation for therapeutic and safety equiv-
alence of such products.
8. Concluding remarks re non-biological complex drugs
When one compares the situation between biologicals and
non-biological complex drugs one should recognize that there
are, in principle, important commonalities between these two
groups of medicines. Both are complex, difﬁcult to characterize
and the production process is key to obtain reproducible product
attributes and subsequent the desired/deﬁned in vivo perfor-
mance. For innovator NBCD products, as for biologicals, this means
that ample attention must be paid to these key aspects before the
clinical test phase can be entered which is also mirrored by the
stepwise approach indicated in the guidance and reﬂection papers
of the FDA and EMA.
It is clear, that in particular in the EU the thinking and resulting
paradigm shift regarding the handling of follow-on versions of bio-
logicals compared to generic, small molecule compounds is way
ahead of the situation around NBCDs. In Fig. 1 the NBCD route is
drawn parallel to the biosimilar route with the same key word: ‘to-
tality of evidence’, and one could add ‘stepwise approach’ to
develop the product. In Europe the centralized procedure should
be the mandatory route for submission of applications. But that
has not been the real situation yet. Companies developing
NBCD-follow-ons can still use the national or mutual recognition
regulatory route and, as mentioned above, that may lead/led to
the approval of ‘NBCD-questionables’. Outside the US and Europe
the situation may differ by country, but in general, there is little
appreciation for the challenges the developers of a follow-on ver-
sion of a NBCD face as illustrated by literature references in all
three NBCD families discussed above. There are also national
authorities, especially in some Asia Pac countries, that give market
access to NBCD-similars/NBCD-questionables in the absence of the
authorization of the innovator product.Further, one can identify the same outstanding issues for NBCDs
as for biosimilars: questions should be answered/actions under-
taken, re: similarity between the regulatory views worldwide (role
WHO?), re: comparability and product attribute drift, re
NBCD-questionables, re extrapolation, re interchangeability and
substitution, re naming.
There is a lot to be done!9. Epilogue
This conference gave food for thought. The pharmaceutical
science community should engage in answering the pending ques-
tions around complex drugs. We need even better tools in the ana-
lytical toolbox, better preclinical tests in vitro and in animals, but
only if relevant, and last but not least to measure efﬁcacy and
safety in the clinic using the proper read-out parameters (new
biomarkers?). And make sure this material is published both by
the innovator and follow-on product manufacturers! The
NBCD-working group, hosted at the Dutch Top Institute Pharma
is stimulating dissemination of science based information and dis-
cussions on the regulatory aspects of NBCDs.
Finally, we should educate and train experts who understand
and appreciate the complexity of this ﬁeld. For biologicals there
are ample teaching facilities/initiatives and relevant text books
and dedicated journals. For NBCDs there is only a beginning
(Crommelin and De Vlieger, 2015), but certain Journals like the
Generics and Biosimilars Initiative (GaBi) are also starting to regu-
larly publish material on NBCDs.References
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